![]() ![]() This is largely because the nanoparticles developed and tested in vitro do not necessarily reflect the in vivo performance, especially when drug release is also dependent on polymer degradation. (7) Despite recent advances in the development of drug delivery nanoparticles with precisely controlled colloidal and functional properties, their translation to clinical use remains challenging. (6) An optimally designed drug delivery system should ensure the availability of the drug at a specific location for a required period of time. ![]() (5) Furthermore, colloidal (e.g., size, composition, loading efficiency) and functional (e.g., release profile) properties of nanoparticles can be adjusted to achieve the desired therapeutic effects. (1−4) Entrapment of drugs within polymeric nanoparticles (NPs) offers the advantages of reduced toxicity and systemic side effects, as well as improved stability and targeted delivery of the drug. ![]() The results of this study expand our knowledge on drug release and degradation behavior of PLGA nanoparticles under different physiological conditions, which will prove useful for the rational design of PLGA-based formulations for various applications that can be translated into clinical practice.ĭrug delivery systems utilizing polymeric nanocarriers have emerged as versatile tools with tremendous potential in clinical applications. PLGA nanoparticles systemically administered to mice predominantly accumulate in the liver, in which FRET no longer takes place at time points as early as 24 h postadministration as determined by ex vivo organ imaging and flow cytometry analysis. Accordingly, PLGA nanoparticles are colloidally stable for more than 2 weeks when incubated in aqueous buffers in situ, whereas in vitro particle degradation starts in between 24 and 48 h, reaching a complete loss of FRET at 72 h as shown with fluorescence microscopy imaging and flow cytometry analysis. The stability of PLGA nanoparticles is studied via monitoring the variations of fluorescence emission characteristics along with colloidal characterization. Here, we present the FRET-based stability assessment of poly(lactic- co-glycolic acid) (PLGA) nanoparticles encapsulating BODIPY-FL12 and Nile Red as the donor and acceptor, respectively. Förster resonance energy transfer (FRET)-based fluorescence labeling approaches are promising tools to study nanoparticle stability under different physiological conditions. Over the years, Tagit has won multiple awards including the Emerging Enterprise Award in Singapore, and has been ranked among the Technology Fastest 500 in Asia by Deloitte.The knowledge of in vitro and in vivo stability of polymeric nanoparticles is vital for the development of clinical formulations for drug delivery and cell labeling applications. The Mobeix platform has been audited and found to be in compliance with requirements of Payment Application Data Security Standard Version 2.0įounded in 2004 by a team that is passionate about mobility, the company is headquartered in Singapore, with offices in Canada, Malaysia, India and Indonesia. The Mobeix platform delivers innovative and engaging mobile experiences that increase market reach and speed up time-to-market, while reducing complexities and protecting existing IT investments. Our robust Mobile Application Development Platform – Mobeix – seamlessly and securely integrates with your current IT assets to provide scalable mobility solutions across multiple mobile devices and operating systems. Millions of users across the globe use Tagit’s applications every day. We work closely with our customers to shape mobile strategies and deliver innovative and secure mobility solutions. We have a highly successful track record in designing, developing and deploying industry-specific mobile applications for leading financial institutions across Asia, Middle East and North America. Tagit’s mobility platform Mobeix enables banks and enterprises to rapidly build secure, scalable and innovative mobile applications. Tagit is an award-winning Singapore-based mobile solutions company.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |